798 related articles for article (PubMed ID: 11485970)
1. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
[TBL] [Abstract][Full Text] [Related]
2. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.
Li YY; McTiernan CF; Feldman AM
Cardiovasc Res; 2000 May; 46(2):214-24. PubMed ID: 10773225
[TBL] [Abstract][Full Text] [Related]
3. Matrix Metalloproteinases in Myocardial Infarction and Heart Failure.
DeLeon-Pennell KY; Meschiari CA; Jung M; Lindsey ML
Prog Mol Biol Transl Sci; 2017; 147():75-100. PubMed ID: 28413032
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase inhibition and the prevention of heart failure.
Lee RT
Trends Cardiovasc Med; 2001 Jul; 11(5):202-5. PubMed ID: 11597832
[TBL] [Abstract][Full Text] [Related]
5. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.
Spinale FG; Coker ML; Bond BR; Zellner JL
Cardiovasc Res; 2000 May; 46(2):225-38. PubMed ID: 10773226
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.
Briasoulis A; Tousoulis D; Papageorgiou N; Kampoli AM; Androulakis E; Antoniades C; Tsiamis E; Latsios G; Stefanadis C
Curr Top Med Chem; 2012; 12(10):1214-21. PubMed ID: 22519451
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs.
Yarbrough WM; Mukherjee R; Brinsa TA; Dowdy KB; Scott AA; Escobar GP; Joffs C; Lucas DG; Crawford FA; Spinale FG
J Thorac Cardiovasc Surg; 2003 Mar; 125(3):602-10. PubMed ID: 12658202
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.
Li YY; Feldman AM
Drugs; 2001; 61(9):1239-52. PubMed ID: 11511020
[TBL] [Abstract][Full Text] [Related]
9. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.
Peterson JT; Li H; Dillon L; Bryant JW
Cardiovasc Res; 2000 May; 46(2):307-15. PubMed ID: 10773235
[TBL] [Abstract][Full Text] [Related]
10. Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium.
Wilson EM; Spinale FG
Ann Med; 2001 Dec; 33(9):623-34. PubMed ID: 11817657
[TBL] [Abstract][Full Text] [Related]
11. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system.
Pauschinger M; Chandrasekharan K; Schultheiss HP
Heart Fail Rev; 2004 Jan; 9(1):21-31. PubMed ID: 14739765
[TBL] [Abstract][Full Text] [Related]
12. Myocardial infarct expansion and matrix metalloproteinase inhibition.
Mukherjee R; Brinsa TA; Dowdy KB; Scott AA; Baskin JM; Deschamps AM; Lowry AS; Escobar GP; Lucas DG; Yarbrough WM; Zile MR; Spinale FG
Circulation; 2003 Feb; 107(4):618-25. PubMed ID: 12566376
[TBL] [Abstract][Full Text] [Related]
13. The plasminogen-MMP system is more activated in the scar than in viable myocardium 3 months post-MI in the rat.
Gaertner R; Jacob MP; Prunier F; Angles-Cano E; Mercadier JJ; Michel JB
J Mol Cell Cardiol; 2005 Jan; 38(1):193-204. PubMed ID: 15623436
[TBL] [Abstract][Full Text] [Related]
14. Effect of matrix metalloproteinase inhibition by doxycycline on myocardial healing and remodeling after myocardial infarction.
Tessone A; Feinberg MS; Barbash IM; Reich R; Holbova R; Richmann M; Mardor Y; Leor J
Cardiovasc Drugs Ther; 2005 Dec; 19(6):383-90. PubMed ID: 16435072
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases.
Siasos G; Tousoulis D; Kioufis S; Oikonomou E; Siasou Z; Limperi M; Papavassiliou AG; Stefanadis C
Curr Top Med Chem; 2012; 12(10):1132-48. PubMed ID: 22519444
[TBL] [Abstract][Full Text] [Related]
16. Myocardial extracellular matrix remodeling in ischemic heart failure.
Gallagher GL; Jackson CJ; Hunyor SN
Front Biosci; 2007 Jan; 12():1410-9. PubMed ID: 17127391
[TBL] [Abstract][Full Text] [Related]
17. Integration of concepts: cardiac extracellular matrix remodeling after myocardial infarction.
Cleutjens JP; Creemers EE
J Card Fail; 2002 Dec; 8(6 Suppl):S344-8. PubMed ID: 12555143
[TBL] [Abstract][Full Text] [Related]
18. Targeting MMP-2 to treat ischemic heart injury.
Hughes BG; Schulz R
Basic Res Cardiol; 2014 Jul; 109(4):424. PubMed ID: 24986221
[TBL] [Abstract][Full Text] [Related]
19. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window.
Vanhoutte D; Schellings M; Pinto Y; Heymans S
Cardiovasc Res; 2006 Feb; 69(3):604-13. PubMed ID: 16360129
[TBL] [Abstract][Full Text] [Related]
20. Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig.
Goetzenich A; Hatam N; Zernecke A; Weber C; Czarnotta T; Autschbach R; Christiansen S
J Heart Lung Transplant; 2009 Oct; 28(10):1087-93. PubMed ID: 19782292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
